A Phase 1 interventional study of ABC008 in Inclusion Body Myositis, sponsored by Abcuro, Inc.. Completed at 4 sites in Australia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Abcuro, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).
Participants who successfully complete the SAD EOT visit, and have no emerging safety issues, will be eligible to enroll in Part 2 (MAD). Eligible participants for the MAD part will have inclusion and exclusion criteria (same as those for Part 1) reviewed prior to dosing on MAD Day 1.
Participants who successfully complete the MAD EOT visit, and have no emerging safety issues, will be eligible to enrol in Part 3, MAD Extension.
After the final MAD visit (W48), participants will have the option to continue on to Part 3 MAD Extension.
For Part 3 (MAD Extension), participant dosing will be at 8-week intervals starting at Day 1. Duration of dosing in Part 3 will be up to approximately 80 weeks (18 months), or until a new long-term extension study has been initiated. The SMC will review all participant safety data approximately every 6 months while the Part 3 dosing continues.
65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.
This study's enrollment of 19 is below the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.
Browse Myositis, Inclusion Body studies →Abcuro, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Dose 0.1 mg / kg ABC008
Drug: ABC008
Single Dose 0.5 mg / kg ABC008
Drug: ABC008
Single Dose 2.0 mg / kg ABC008
Drug: ABC008
Single Dose 5.0 mg / kg ABC008
Drug: ABC008
X.X mg / kg ABC008
Drug: ABC008
Single 2.0 mg / kg ABC008
Drug: ABC008
Multiple Dose 0.1 mg / kg ABC008 every 8 weeks
Drug: ABC008
Multiple Dose 0.5 mg / kg ABC008 every 8 weeks
Drug: ABC008
Multiple Dose 2.0 mg / kg ABC008 every 8 weeks
Drug: ABC008
ABC008
Assessment of Safety and Tolerability
Characterize the safety and tolerability profile of single (SAD) and multiple (MAD) escalating dose levels of ABC008 in IBM when administered subcutaneously (SC) as measured by the number and severity of treatment emergent adverse events, serious adverse events, and adverse events of special interest, number of dose limiting toxicities.
Time frame: Through Study Completion an average of 28 weeks for SAD (Single Ascending Dose) phase and 52 weeks for MAD (Multiple Ascending Dose) phase]
Assessment of peak serum concentration (Cmax)
Assess the peak serum concentration (Cmax) of a single dose of ABC008
Time frame: Day 1 and throughout the 24 weeks of follow up
Assessment of time to peak serum concentration (Tmax)
Assess the time to peak serum concentration (Tmax) of a single dose of ABC008
Time frame: Day 1 and throughout the 24 weeks of follow up
Assessment of terminal half-life (t½)
Assess the terminal half-life (t½) of ABC008
Time frame: Day 1
Assessment of area under the concentration versus time curve from time zero to 24 hours post-dose (AUC0-24hr)
Assess the area under the concentration versus time curve of a single dose of ABC008 from time zero to 24 hours post-dose (AUC0-24hr)
Time frame: Day 1
Assessment of apparent clearance (CL/F)
Assessment of apparent clearance (CL/F) of a single dose of ABC008
Time frame: Day 1 and throughout the 24 weeks of follow up
Assessment of apparent volume of distribution (Vz/F)
Assessment of apparent volume of distribution (Vz/F) of a single dose of ABC008
Time frame: Day 1 and throughout the 24 weeks of follow up
Characterization of changes in KLRG1 expressing lymphocytes
Characterize changes in KLRG1 expressing lymphocytes
Time frame: Day 1 and throughout the 24 weeks of follow up
Qualitative assessment of [ 89Zr]Zr-Df-crefmirlimab
Qualitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites as determined by using a visual scoring (VS) system for the time point assessed, the possible scores VS1-VS5
Time frame: [Through Study Completion, avg. 48 weeks
Assessment of global distribution of [ 89Zr]Zr-Df-crefmirlimab uptake in skeletal muscle
Assessment of global distribution of \[ 89Zr\]Zr-Df-crefmirlimab uptake in skeletal muscle; Pattern(s) of absolute and relative changes in uptake within various skeletal muscle groups; Homogenous/diffuse, Focal, Mixed, Other
Time frame: [Through Study Completion, avg. 48 weeks
Assessment of global distribution of [ 89Zr]Zr-Df-crefmirlimab uptake in lymphoid organs
Assessment of global distribution of \[ 89Zr\]Zr-Df-crefmirlimab uptake in lymphoid organs; Uptake and relative changes in uptake within lymphoid tissue including spleen and lymph nodes as well as other T-cell rich tissues such as bone marrow
Time frame: [Through Study Completion, avg. 48 weeks
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab pre and post dosing of ABC008
Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake and relative changes in uptake within inflamed muscle tissue through Positron Emission Tomography (PET)/computed tomography (CT) imaging pre- and post-dosing with ABC008
Time frame: [Through Study Completion, avg. 48 weeks
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis peak (SUVpeak)
Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis peak (SUVpeak)
Time frame: [Through Study Completion, avg. 48 weeks
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis mean (SUVmean)
Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis mean (SUVmean)
Time frame: [Through Study Completion, avg. 48 weeks
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis SUV of diseased muscle
Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis SUV of diseased muscle
Time frame: [Through Study Completion, avg. 48 weeks
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis SUV reference tissue
Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis SUV reference tissue
Time frame: [Through Study Completion, avg. 48 weeks
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis maximum (SUVmax)
Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis maximum (SUVmax)
Time frame: [Through Study Completion, avg. 48 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2021 to primary completion in Jan 2025, 43 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ulviprubart
Abcuro, Inc.